Biotech
SAN FRANCISCO, CA and TOKYO, JAPAN: Study Will Be Stopped Early and Enzalutamide Will Be Offered to All Qualified Study Participants; 30% Reduction in the Risk of Death, Hazard Ratio=0.70 (p < 0.0001); 81% Reduction in the Risk of Ra ...
KING OF PRUSSIA, PA: Patients Lost During a Clinical Trial Result in Study Delays, Increased Patient Recruitment Costs and Compromised Study Data
...
BEDFORD, MA: Responsive Design Technology Improves Website Experience for Mobile Devices
...
SOUTH SAN FRANCISCO, CA: Clinical Data on TH-302 Combinations With Votrient(R) (Pazopanib) and Sutent(R) (Sunitinib) as Well as Preclinical Data on TH-302 Combination With Abraxane(R) (Nab-Paclitaxel) to Be Presented at the A ...
BERKELEY, CA: Conference Call Tomorrow, October 17th at 8:30 a.m. ET
...
